The FDA has accepted a supplemental New Drug Application and granted Priority Review for empagliflozin for the treatment of adults with HF independent of LVEF.
AHA 2021 This analysis of the EMPEROR-Preserved trail showed that empagliflozin reduced the primary endpoint of time to first event of CV death or HF hospitalization by 17%, compared to placebo, in HF patients with LVEF ≥50%.
AHA 2021 The CHIEF-HF study showed that canagliflozin improved symptoms in HF as measured by KCCQ-TSS. The benefits with canagliflozin were observed as early as 2 weeks and sustained until the end of treatment at 3 months.
Managing patients with diabetes requires a team approach of physicians in primary care, nephrologists, cardiologists and diabetologists. In this e-learning course, the discussants present a case of a patient with diabetes and comorbidities that shows the complexity of management of such a patient.
The SGLT2 inhibitor dapagliflozin reduced albuminuria compared to placebo in CKD patients with and without T2DM in the DAPA-CKD trial, with a more pronounced effect in patients with T2DM.
A prespecified analysis of the DAPA-CKD trial demonstrated that treatment with dapagliflozin attenuated the decline in eGFR compared with placebo, with a greater effect in those with T2DM, higher HbA1c and higher UACR.
This phase II randomized study showed that empagliflozin improved vascular function parameters in patients with HF under office conditions and in 24h ambulatory measurements compared to baseline as well as compared to placebo.
Watch the entire symposium on teaming up to tackle cardiorenal risk in diabetes - The role of SGLT2i: How to overcome clinical inertia?
The SGLT2 inhibitor empagliflozin reduced the risk of the primary endpoint, HF hospitalization and renal outcomes independently of baseline SBP, in patients with HFrEF in the EMPEROR-Reduced trial.
Reduction of CV and renal outcomes by empagliflozin in HFrEF patients in the EMPEROR-Reduced trial was independent of baseline NT-proBNP levels. Empagliflozin reduced NT-proBNP levels, which was associated with a reduction in adverse outcomes.
EASD 2021 This secondary analysis of the DAPA-CKD trial showed that the efficacy and safety of dapagliflozin on kidney and CV outcomes was consistent across subgroups of baseline albuminuria in patients with CKD, with and without T2DM.
EASD 2021 There is a wide distribution of 10-year and lifetime CV risk in diabetes patients with and without a history of CVD. Use of SGLT2 inhibitors and GLP-1RAs was low in all groups.